Physician profile
Talara Hedgpeth
NPI 1346779873
$1,006.04
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2022: $251 · 2023: $398 · 2024: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $203.21 | 2021-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.82 | 2022-2023 | Lifevest |
| Novo Nordisk INC | $125.00 | 2022 | |
| Abbvie INC. | $124.19 | 2024 | |
| Novartis Pharmaceuticals Corporation | $105.27 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $101.62 | 2021-2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $101.24 | 2023 | |
| Glaxosmithkline, LLC. | $50.62 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $31.80 | 2021-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $17.99 | 2023 | Uptravi |
| Amgen INC. | $17.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talara Hedgpeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.